December saw shares of Rigel Pharmaceuticals (RIGL 3.84%) drop more than 20%. The tumble happened after Rigel's partner AstraZeneca (AZN -0.24%) released phase 2b data concerning their experimental rheumatoid arthritis drug fostamatinib. While the drug outperformed the placebo, it failed to beat AbbVie's (ABBV -2.40%) Humira. (AbbVie, formerly the branded pharmaceutical division of health care powerhouse Abbott Labs (ABT 0.55%), is now listed on the NYSE). In this video, Motley Fool health care analysts Max Macaluso and Brenton Flynn break down this story for investors.